Oncotelic Therapeutics, Inc.
OTLC
$0.03
$0.001.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 39.65% | -634.45% | 41,762.19% | 68.30% | 232.46% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 270.62% | 274.29% | 1,150.00% | 268.24% | -34.37% |
| Total Other Non-Cash Items | -48.59% | 29,409.68% | -68,340.01% | -83.14% | -499.57% |
| Change in Net Operating Assets | 73.43% | -212.32% | -321.32% | 37.93% | 533.74% |
| Cash from Operations | 26.94% | -104.91% | -653.61% | -114.39% | 51.80% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 41.41% | 129.38% | 1,029.02% | 185.45% | -6.90% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 58.96% | 98.13% | 1,029.02% | 185.45% | -6.90% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,290.91% | -260.00% | -408.90% | 317.97% | 107.53% |